Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INBRX-105 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Inhibrx
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
INBRX-105 + pembrolizumab is a combination therapy consisting of INBRX-105, a bispecific antibody targeting PD-L1 and 4-1BB receptors, and pembrolizumab, a PD-1 checkpoint inhibitor. INBRX-105 provides dual mechanism of action through PD-L1 blockade and conditional 4-1BB agonism that is dependent on PD-L1 engagement, designed to enhance anti-tumor immune responses while avoiding hepatotoxicity associated with systemic 4-1BB agonism.
- Other names
- INBRX-105 with pembrolizumabINBRX105 with pembrolizumabINBRX 105 with pembrolizumabINBRX-105 plus KeytrudaINBRX105 plus KeytrudaINBRX 105 plus Keytruda
02
Targets
TNFRSF9 (CD137 extracellular domain)PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on INBRX-105 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INBRX-105 + pembrolizumab.